Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Galectin inhibitors target galectins, animal lectins that bind β-galactoside sugars on glycoproteins. Each galectin carries at least one conserved carbohydrate recognition domain (CRD), which recognizes lactose and N-acetyllactosamine units in glycans. By cross-linking glycoproteins, galectins influence cell adhesion, immune cell signaling, fibrosis and tumor progression. Galectin-1 and galectin-3 are the family members most studied with small molecules. Many inhibitors mimic the natural sugar ligands, from the disaccharide thiodigalactoside to synthetic galectin-3 ligands such as GB1107 and selvigaltin. Belapectin is a complex plant-derived polysaccharide studied as a galectin-3 inhibitor. OTX008, a calixarene derivative, is listed as a galectin-1 inhibitor.
DB21 is a Galectin-1 antagonist that functions as an allosteric inhibitor of galectin-1 binding to cell surface glycans. This dibenzofuran-conjugated peptidomimetic demonstrates significant inhibition of angiogenesis and tumor growth in models of melanoma, lung adenocarcinoma, and ovarian cancer. Its ability to disrupt galectin-1 interactions positions DB21 as a valuable tool for cancer research and therapeutic development.
Out of stock
All 3 sizes
SNAP 398299 is a selective antagonist of the Galectin-3 (Gal3) receptor. This compound has demonstrated potential anxiolytic and antidepressant effects by partially reversing the neuropeptide galanin-induced inhibition of dorsal raphe neuronal firing as well as the galanin-induced hyperpolarizing current. Its unique mechanism makes SNAP 398299 a valuable tool for researching the roles of galectin in neurobiology and potential therapeutic interventions for mood disorders.
